证券代码：603858 证券简称：步长制药 公告编号：2025-166 山东步长制药股份有限公司 关于控股子公司减少注册资本的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、交易概述 （一）基本情况 本次减资事项不构成关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。 二、本次减资主体基本情况 （一）基本信息 山东步长制药股份有限公司（以下简称"公司"）于 2025 年 6 月 24 日召开 第五届董事会第二十六次会议，审议通过了《关于控股子公司减少注册资本的议 案》，拟将江苏合璞医疗科技有限公司（以下简称"江苏合璞"）的注册资本由 5,020 万元减少至 200 万元。具体内容详见公司于 2025 年 6 月 25 日披露于上海 证券交易所网站（www.sse.com.cn）的《关于控股子公司减少注册资本的公告》 （公告编号：2025-122）。 依据江苏省《冠"江苏"行政区划的企业名称登记工作规定（2016 修订）》 （苏工商审批〔2016〕58 号），冠名"江苏"前缀的公司 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-164 山东步长制药股份有限公司 公司控股子公司山东步长药妆生物科技有限公司（以下简称"步长药妆"）、 山东步长鼎晟药业有限公司（以下简称"步长鼎晟"）和山东步长传方药业有限 公司（以下简称"步长传方"）因经营管理之需要，拟对法定代表人进行变更。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《关 于控股子公司法定代表人变更的公告》（公告编号：2025-165） 本议案已经公司董事会战略与投资委员会审议通过，同意提交董事会审议。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、《关于控股子公司减少注册资本及变更注册地址的议案》 鉴于公司业务发展需要，为进一步整合资源、优化资源配置、提高资金使用 效率，公司控股子公司上海合璞医疗科技有限公司拟对其全资子公司江苏合璞医 疗科技有限公司（以下简称"江苏合璞"）进行减资及变更注册地址。本次减资 完成后，江苏合璞的注册资本将由 5,020 万元减少至 500 万元。 1 第五届董事会第三十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 ...

Core Viewpoint - The company has decided to optimize resource allocation and reduce management costs by proposing the cancellation of its subsidiary, Step Long (Guangzhou) Medical Diagnostic Technology Co., Ltd. [1] Group 1 - The fifth session of the company's board of directors held on September 4, 2025, approved the proposal to cancel Step Long (Guangzhou) Medical Diagnostic Technology Co., Ltd. [1] - The decision is part of a broader strategy to enhance operational efficiency within the company [1]

Core Viewpoint - The company announced the transfer of shares in its subsidiary, Buchang Dingsheng, with a total of 5% of equity being sold to individuals for a nominal amount, resulting in the company retaining a 94% ownership stake in the subsidiary [1]. Group 1 - Shareholder Zhao Lu plans to transfer 3.00% of his shares in Buchang Dingsheng for 42,366 yuan to Xie Jihui [1] - Shareholder Guo Yubiao intends to transfer 1.00% of his shares in Buchang Dingsheng for 14,122 yuan to Xie Jihui [1] - Shareholder Cai Yunfei will transfer 1.00% of his shares in Buchang Dingsheng for 14,122 yuan to He Tao [1] Group 2 - The company has agreed to waive its preferential right to acquire the aforementioned shares [1] - After the completion of these transfers, the company will hold a 94.00% stake in Buchang Dingsheng [1]

格隆汇9月5日丨步长制药(603858.SH)公布，公司拟以0元人民币受让赵路持有的公司控股子公司步长药 妆1.50%未实缴部分股权。赵路拟将其未实缴的步长药妆1.00%股权转让给谢继辉、0.50%股权转让给王 奇，上述股权转让价格均为0元；公司同意放弃上述股权转让的优先受让权。股权转让完成后，公司持 有步长药妆94.50%股权比例。 ...

Core Viewpoint - The company, Buchang Pharma (603858.SH), announced the transfer of equity stakes in Buchang Chuanfang, resulting in a reduction of its ownership to 92.5% after the transactions [1] Group 1: Equity Transfer Details - Buchang Pharma plans to transfer 0.50% of its stake in Buchang Chuanfang to He Tao for 0.6875 million RMB [1] - Zhao Lu intends to transfer a total of 3.00% of his stake in Buchang Chuanfang, with specific allocations: 1.00% to Xie Jihui for 1.375 million RMB, and 0.50% each to Xu Bao, Gao Ge Yan, Chen Mei Shou, and He Qian, each for 0.6875 million RMB [1] - The company has agreed to waive its preferential right to acquire the transferred equity [1]

格隆汇9月5日丨步长制药(603858.SH)公布，公司控股子公司上海合璞拟对其全资子公司江苏合璞进行 减资。本次减资完成后，江苏合璞的注册资本将由5,020万元减少至500万元，上海合璞仍持有江苏合璞 100%股权。 ...

Core Viewpoint - The company plans to optimize resource allocation and reduce management costs by proposing the cancellation of its subsidiaries, Changsha Zhongce Biotechnology Co., Ltd. and Hunan Zhongce Biotechnology Co., Ltd. [1] Group 1 - The company held its 31st meeting of the 5th Board of Directors on September 4, 2025, where the proposal for the cancellation of the subsidiaries was approved [1] - The cancellation of the subsidiaries is not expected to have a substantial impact on the company's consolidated financial statements [1] - The overall business development and profitability of the company will remain unaffected by this cancellation [1]

Group 1 - The company has signed a maximum guarantee contract with Beijing Bank Xi'an Branch, providing a joint liability guarantee of 100 million yuan for its wholly-owned subsidiary Yangling Buchang Pharmaceutical Co., Ltd. [1][5] - The company and its subsidiaries have approved a total financing limit of up to 6.92 billion yuan for 2025, with a guarantee limit not exceeding 6.92 billion yuan, including a new guarantee limit of 2.6 billion yuan for the company itself [2][4] - The total amount of guarantees provided by the company and its subsidiaries is 2.5403079 billion yuan, accounting for 24.86% of the company's audited net assets as of the end of 2024, with no overdue guarantees reported [12] Group 2 - The guarantee is necessary for Yangling Buchang to meet its daily operational needs and is expected to positively impact the company's development and efficiency [10] - The board of directors believes that the subsidiary is stable and capable of fulfilling its obligations, and the guarantee does not harm the interests of the company or its shareholders [11] - The guarantee period is three years from the maturity of the guaranteed debt, covering all debts under the main contract, including principal, interest, penalties, and other related costs [8]

证券代码：603858 证券简称：步长制药 公告编号：2025-163 山东步长制药股份有限公司 关于为公司全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计担保情况 | 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 254,030.79 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 24.86 | | 特别风险提示（如有请勾选） | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最 | | | 近一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达 | | | 到或超过最近一期经审计净资产 30% | | | ☑本次对资产负债率超过 70%的单位提供担 | | 保 | | 一、担保情况概述 （一）担保的基本情况 山东步长制药股份有限公司（以下简称"公司"）于 2 ...